| Response | Remission | |||||||
---|---|---|---|---|---|---|---|---|---|
Study /sample size | OR (95%CI) | I2 (%) | Pbetween | Study /sample size | OR (95%CI) | I2 (%) | Pbetween | ||
Study design | Single-center | 2/120 | 2.13 (0.96, 4.73) | 0 | 0.26 | 3/268 | 3.96 (2.32, 6.78) | 50 | < 0.01 |
Multi-center | 7/4509 | 1.34 (1.04,1.77) | 60 | 7/4022 | 1.62 (1.34, 1.95) | 0 | |||
Sample size | < 200 | 4/549 | 1.66 (1.13, 2.45) | 35 | 0.27 | 6/804 | 2.36 (1.37, 4.05) | 57 | 0.07 |
≥ 200 | 5/4080 | 1.29 (0.97, 1.72) | 62 | 4/3486 | 1.61 (1.31, 1.98) | 0 | |||
Population | Caucasian | 7/4458 | 1.31 (1.14, 1.50) | 47 | 0.03 | 7/3971 | 1.59 (1.31, 1.92) | 0 | < 0.01 |
Asian | 2/171 | 2.70 (1.42, 5.13) | 0 | 2/171 | 2.27 (1.20, 4.28) | 0 | |||
NA | - | - | - | Â | 1/107 | - | - | Â | |
Diagnostic criteria | HAM-D17 | 8/2555 | 1.57 (1.11, 2.23) | 60 | 0.48 | 9/2535 | 1.95 (1.24, 3.07) | 71 | 0.46 |
PHQ-9 | 2/3243 | 1.37 (1.17, 1.60) | 0 | 2/3243 | 1.42 (1.16, 1.74) | 0 | |||
Industry funding | Fully | 3/606 | 1.37 (0.62, 3.00) | 81 | 0.70 | 3/290 | 4.89 (2.81, 8.52) | 0 | < 0.01 |
Partially | 5/3952 | 1.37 (1.18, 1.59) | 17 | 6/3929 | 1.57 (1.30, 1.90) | 0 | |||
None | 1/71 | - | - | 1/71 | - | - |